drugset
drugset / Trial / NCT05704985

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

NCT05704985 ↗

Phase 1 Active not recruiting 39 enrolled DEKA Biosciences
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.

Timeline

Start
2023-04-03
Primary completion
2025-07
Completion
2025-10

Drugs

EvaluationDrugModalityDoseRoute
Subject DK210 Unknown 0.025 mg/kg Subcutaneous
Subject DK210 Unknown 0.3 mg/kg Subcutaneous
Background Capecitabine Small molecule — Intravenous
Background Carboplatin Small molecule — Intravenous
Background Nivolumab Monoclonal antibody — Intravenous
Background Oxaliplatin Small molecule — Intravenous
Background Paclitaxel Small molecule — Intravenous
Background Pembrolizumab Monoclonal antibody — Intravenous
Background fluorouracil Small molecule — Intravenous

Indications

colorectal cancer female reproductive organ cancer head and neck cancer kidney cancer malignant pancreatic neoplasm non-small cell lung carcinoma skin cancer